JP2008512350A - 標的化され、そして高密度で薬物が負荷されるポリマー性物質 - Google Patents

標的化され、そして高密度で薬物が負荷されるポリマー性物質 Download PDF

Info

Publication number
JP2008512350A
JP2008512350A JP2007519462A JP2007519462A JP2008512350A JP 2008512350 A JP2008512350 A JP 2008512350A JP 2007519462 A JP2007519462 A JP 2007519462A JP 2007519462 A JP2007519462 A JP 2007519462A JP 2008512350 A JP2008512350 A JP 2008512350A
Authority
JP
Japan
Prior art keywords
microparticle
microparticles
polymer
ligand
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007519462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512350A5 (https=
Inventor
ウィリアム マーク サルツマン，
タレク ファハミー，
ピーター フォン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2008512350A publication Critical patent/JP2008512350A/ja
Publication of JP2008512350A5 publication Critical patent/JP2008512350A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2007519462A 2004-07-01 2005-06-30 標的化され、そして高密度で薬物が負荷されるポリマー性物質 Withdrawn JP2008512350A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58504704P 2004-07-01 2004-07-01
US61682104P 2004-10-07 2004-10-07
US62877804P 2004-11-17 2004-11-17
US67799105P 2005-05-05 2005-05-05
PCT/US2005/023444 WO2006080951A2 (en) 2004-07-01 2005-06-30 Targeted and high density drug loaded polymeric materials

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014210425A Division JP6031077B2 (ja) 2004-07-01 2014-10-15 標的化され、そして高密度で薬物が負荷されるポリマー性物質

Publications (2)

Publication Number Publication Date
JP2008512350A true JP2008512350A (ja) 2008-04-24
JP2008512350A5 JP2008512350A5 (https=) 2008-08-07

Family

ID=36740923

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007519462A Withdrawn JP2008512350A (ja) 2004-07-01 2005-06-30 標的化され、そして高密度で薬物が負荷されるポリマー性物質
JP2014210425A Expired - Lifetime JP6031077B2 (ja) 2004-07-01 2014-10-15 標的化され、そして高密度で薬物が負荷されるポリマー性物質
JP2016161691A Expired - Lifetime JP6407218B2 (ja) 2004-07-01 2016-08-22 標的化され、そして高密度で薬物が負荷されるポリマー性物質
JP2018051082A Pending JP2018100295A (ja) 2004-07-01 2018-03-19 標的化され、そして高密度で薬物が負荷されるポリマー性物質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014210425A Expired - Lifetime JP6031077B2 (ja) 2004-07-01 2014-10-15 標的化され、そして高密度で薬物が負荷されるポリマー性物質
JP2016161691A Expired - Lifetime JP6407218B2 (ja) 2004-07-01 2016-08-22 標的化され、そして高密度で薬物が負荷されるポリマー性物質
JP2018051082A Pending JP2018100295A (ja) 2004-07-01 2018-03-19 標的化され、そして高密度で薬物が負荷されるポリマー性物質

Country Status (6)

Country Link
US (5) US7534449B2 (https=)
EP (1) EP1768692B8 (https=)
JP (4) JP2008512350A (https=)
AU (2) AU2005326322B2 (https=)
CA (1) CA2571899A1 (https=)
WO (1) WO2006080951A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540162A (ja) * 2010-10-22 2013-10-31 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 抗原特異的な寛容を誘導する微粒子およびその使用
JP2016128404A (ja) * 2009-03-31 2016-07-14 ユニベルシテ ダンジュ 官能化された脂質カプセルを調製する為の方法
JP2016536312A (ja) * 2013-11-01 2016-11-24 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法のための調節粒子
WO2022050369A1 (ja) 2020-09-04 2022-03-10 国立大学法人大阪大学 抗菌薬を含有するリポソーム製剤

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB0121980D0 (en) * 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
US7182779B2 (en) 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7309350B2 (en) 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7351255B2 (en) 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US7147656B2 (en) 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US20030135266A1 (en) 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
KR20060085246A (ko) * 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7326236B2 (en) 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
EP1713514B1 (en) * 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US20050288766A1 (en) * 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US8728526B2 (en) * 2004-08-19 2014-05-20 The United States of America, Represented by Secretary of Department of Health and Human Services, NIH Coacervate microparticles useful for the sustained release administration of therapeutic agents
AU2005279772A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
WO2006026554A1 (en) * 2004-08-30 2006-03-09 Neville Alleyne Method of using an implant for treatment of ligaments and tendons
US7985426B1 (en) * 2004-10-05 2011-07-26 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells and delivery means
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
CN101008643B (zh) * 2006-01-23 2013-03-27 中国人民解放军军事医学科学院生物医学分析中心 一种金属螯合纳米磁珠,其制备方法及应用
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007227000A1 (en) 2006-03-20 2007-09-27 Xtent, Inc. Apparatus and methods for deployment of linked prosthetic segments
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007133801A2 (en) * 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007146319A2 (en) * 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2061433B1 (en) * 2006-09-08 2011-02-16 Johns Hopkins University Compositions for enhancing transport through mucus
US8563022B2 (en) * 2006-10-11 2013-10-22 Board Of Regents Of The University Of Texas System Particles for cell targeting
JP5227326B2 (ja) * 2006-11-03 2013-07-03 ボストン サイエンティフィック リミテッド 薬物を溶出する被覆を有するステント
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
US20110223664A1 (en) * 2006-11-16 2011-09-15 The University Of Akron Materials and methods of introducing genetic material into living cells
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
WO2008067384A2 (en) 2006-11-30 2008-06-05 Wilson-Cook Medical, Inc. Visceral anchors for purse-string closure of perforations
US20080146489A1 (en) * 2006-12-15 2008-06-19 Pacetti Stephen D Regional delivery of therapeutic agents for the treatment of vascular diseases
US7850382B2 (en) * 2007-01-18 2010-12-14 Sanford, L.P. Valve made from two materials and writing utensil with retractable tip incorporating same
US7488130B2 (en) 2007-02-01 2009-02-10 Sanford, L.P. Seal assembly for retractable instrument
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US8889117B2 (en) * 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
CN101678090B (zh) 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
MX2009010907A (es) 2007-04-13 2010-03-17 Univ North Texas Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
US9044385B2 (en) * 2007-05-16 2015-06-02 Abbott Cardiovascular Systems Inc. Therapeutic compositions for targeted vessel delivery
WO2008147875A1 (en) * 2007-05-31 2008-12-04 Wilson-Cook Medical, Inc. Suture lock
US8889140B2 (en) * 2007-05-31 2014-11-18 Transtarget, Inc. Compositions and methods for tissue repair
US20080299172A1 (en) * 2007-06-04 2008-12-04 Stuart Young Tissue repair implant
US7901452B2 (en) * 2007-06-27 2011-03-08 Abbott Cardiovascular Systems Inc. Method to fabricate a stent having selected morphology to reduce restenosis
DE102007030931A1 (de) * 2007-07-03 2009-01-08 Birgit Riesinger Zusammensetzung, enthaltend mindestens einen nutritiven, mindestens einen desinfizierenden bzw. dekontaminierenden und/oder mindestens einen Proteasen hemmend wirkenden Wirkstoff und/oder Wirkstoffkomplex
EP2175841A1 (en) * 2007-07-16 2010-04-21 Aarhus Universitet Osteopontin nanoparticles system for drug delivery
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009015112A2 (en) * 2007-07-23 2009-01-29 The University Of Akron Metal complexes incorporated within biodegradable nanoparticles and their use
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
JP5226792B2 (ja) * 2007-09-25 2013-07-03 クック メディカル テクノロジーズ エルエルシー 組織アンカーを使用するための医療器具、装置及び方法
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
JP2011500569A (ja) * 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
WO2009050696A2 (en) * 2007-10-18 2009-04-23 Qray Ltd. Composition and method for cell activation and tissue repair using nanoparticles and light
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009082596A1 (en) * 2007-12-18 2009-07-02 Wilson-Cook Medical, Inc. Device and method for placement of tissue anchors
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2713137C (en) 2008-01-25 2017-10-24 Hadasit Medical Research Services And Development Ltd. Targeting of innate immune response to tumor site
US20100004700A1 (en) * 2008-03-05 2010-01-07 Neville Alleyne Method of treating tissue with a suspenson of tricalcium hydroxyapatite microspheres
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
WO2009114614A2 (en) * 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US8226312B2 (en) * 2008-03-28 2012-07-24 Sanford, L.P. Valve door having a force directing component and retractable instruments comprising same
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2009137438A2 (en) 2008-05-06 2009-11-12 Wilson-Cook Medical Inc. Apparatus and methods for delivering therapeutic agents
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US8728446B2 (en) * 2008-06-03 2014-05-20 I Did It, Inc. Oral hygiene tablets and capsules for direct oral delivery of active ingredients
US8318211B2 (en) * 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US20110105417A1 (en) * 2008-06-26 2011-05-05 The Curators Of The University Of Missouri Drug Conjugates
WO2010017215A2 (en) * 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8221012B2 (en) * 2008-11-07 2012-07-17 Sanford, L.P. Retractable instruments comprising a one-piece valve door actuating assembly
US9283184B2 (en) * 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2010065728A1 (en) * 2008-12-05 2010-06-10 Wilson-Cook Medical, Inc. Tissue anchors for purse-string closure of perforations
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
AU2009330505A1 (en) 2008-12-23 2011-06-30 Cook Medical Technologies Llc Apparatus and methods for containing and delivering therapeutic agents
US8393814B2 (en) 2009-01-30 2013-03-12 Sanford, L.P. Retractable instrument having a two stage protraction/retraction sequence
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
CA2756072A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
AU2010232485B2 (en) * 2009-04-03 2013-11-07 Cook Medical Technologies Llc Medical devices, systems, and methods for rapid deployment and fixation of tissue anchors
US8647368B2 (en) 2009-04-03 2014-02-11 Cook Medical Technologies Llc Tissue anchors and medical devices for rapid deployment of tissue anchors
EP2416762A2 (en) * 2009-04-08 2012-02-15 SurModics, Inc. Controlled release devices and methods for delivery of nucleic acids
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
GB2470378A (en) * 2009-05-20 2010-11-24 Univ Westminster A controlled release composition for intraocular delivery of a therapeutic agent
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
US9101744B2 (en) 2009-05-29 2015-08-11 Cook Medical Technologies Llc Systems and methods for delivering therapeutic agents
US8118777B2 (en) * 2009-05-29 2012-02-21 Cook Medical Technologies Llc Systems and methods for delivering therapeutic agents
US20100324124A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
ES2641892T3 (es) 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
US20110091560A1 (en) * 2009-10-21 2011-04-21 The Burnham Institute For Medical Research Compositions of nanoparticles and methods of making the same
US8808724B2 (en) * 2009-10-28 2014-08-19 Ethicon, Inc. Antimicrobial coatings with preferred microstructure for medical devices
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
US9439941B2 (en) * 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
CN102917690B (zh) 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US8865123B1 (en) 2010-09-16 2014-10-21 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US9119887B2 (en) 2010-09-16 2015-09-01 Mo-Sci Corporation Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging
US9849200B2 (en) 2010-09-16 2017-12-26 Mo-Sci Corporation Strontium phosphate microparticle for radiological imaging and therapy
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
BR112013021731A2 (pt) 2011-02-25 2016-11-01 Univ South Dakota nanopartícula;composição farmacêutica ou cosmética;utilização; método para melhorar a estabilidade de um retinóide;método para melhorar a dispersibilidade de um retinóide; método para proporcinar a libertação sustentada de um retinóide; método para aumentar a penetração na pele de um retinóide;método para aumentar a acumulação de tumor de encapsulamento de droga;método para reduzir a acumulação de drogas em tecidos de rolamento não tumorais; método para reduzir a toxicidade de um retinóide;método para reduzir a irritação da pele classificação de um retinóide aplicado topicamente encapsulante compreendendo uma pluralidade de nanopartículas;método de preparação de uma nanopartícula
BR112013021732B1 (pt) 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
AU2012318273B2 (en) * 2011-12-02 2016-05-19 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
US8632489B1 (en) 2011-12-22 2014-01-21 A. Mateen Ahmed Implantable medical assembly and methods
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
WO2014031883A1 (en) 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014070723A1 (en) * 2012-10-30 2014-05-08 Particle Sciences, Inc. Drug delivery particle formulations with targeting moieties
WO2014074952A1 (en) 2012-11-09 2014-05-15 Massachusetts Institute Of Technology Methods and compositions for localized delivery of agents to hiv-infected cells and tissues
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
CN105120849B (zh) 2013-03-14 2020-08-21 Ran生物技术公司 用于检测生物物质的方法和材料
US10105681B2 (en) * 2013-03-14 2018-10-23 Ran Biotechnologies, Inc. Methods and materials for microorganism capture
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
US9867931B2 (en) 2013-10-02 2018-01-16 Cook Medical Technologies Llc Therapeutic agents for delivery using a catheter and pressure source
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
EP2978408B1 (en) * 2013-03-27 2019-01-16 Centre Hospitaller Universitaire Vaudois (CHUV) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
WO2014176389A1 (en) * 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
AU2014262164B2 (en) * 2013-05-03 2020-02-27 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
BR122020023215B1 (pt) * 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
BR112015030237A2 (pt) 2013-06-04 2017-10-03 Selecta Biosciences Inc Imunoterapêutico antígeno-específico, composição, método de fabricação e seu uso
CA2953287A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
ES2756531T3 (es) 2013-08-22 2020-04-27 Arch Biosurgery Inc Mallas implantables para controlar el movimiento de fluidos
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
CA2924733C (en) 2013-09-29 2018-02-27 St. Jude Children's Research Hospital, Inc. Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
US20170073401A1 (en) 2014-05-02 2017-03-16 Research Institute At Nationwide Children's Hospital Compositions and methods for anti-lyst immunomodulation
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
ES2966886T3 (es) 2014-05-09 2024-04-24 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
US10898593B2 (en) * 2014-05-13 2021-01-26 Yale University Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
WO2015200728A1 (en) 2014-06-25 2015-12-30 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
WO2016115532A1 (en) 2015-01-16 2016-07-21 Spineovations, Inc. Method of treating spinal disk
KR20240126072A (ko) 2015-01-27 2024-08-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
EP3286245A4 (en) 2015-04-21 2018-09-19 Ran Biotechnologies, Inc. Novel fluorinated surfactants
EP3291832B1 (en) 2015-05-06 2025-09-03 UTI Limited Partnership Nanoparticle compositions for sustained therapy
US10385311B2 (en) * 2015-05-27 2019-08-20 Purdue Research Foundation Method of making biological tissue components
US20180161340A1 (en) 2015-06-18 2018-06-14 St. Jude Children's Research Hospital Methods and compositions for the prevention and treatment of hearing loss
WO2017027843A1 (en) 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
CN105363071B (zh) * 2015-11-23 2018-10-09 金仕生物科技（常熟）有限公司 生物材料的抗钙化处理方法
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
KR20180120753A (ko) 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
US20200289666A1 (en) * 2016-03-28 2020-09-17 The Johns Hopkins University Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery
SG11201808528VA (en) * 2016-03-30 2018-10-30 Convatec Technologies Inc Modified wound dressings
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3038089A1 (en) 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
US11559606B2 (en) 2016-12-09 2023-01-24 The Penn State Research Foundation Semi-synthetic tissue constructs for tissue regeneration
MX2019008143A (es) 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
NZ759468A (en) 2017-05-26 2026-03-27 Animal Microbiome Analytics Inc Products and methods for therapeutic administration of microorganisms to non-human animals
IL271275B1 (en) 2017-06-13 2026-04-01 Flagship Pioneering Innovations V Inc Preparations containing croons and their uses
US20180355121A1 (en) * 2017-06-13 2018-12-13 Uvic Industry Partnerships Inc. Multifunctional microcarriers with thermo-responsive biomaterial coating and use thereof
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CN108175864A (zh) * 2018-01-12 2018-06-19 中山大学 一种多模态成像纳米探针及其合成方法
WO2019191456A1 (en) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
CN112654370A (zh) 2018-07-16 2021-04-13 西莱克塔生物科技公司 Mma构建体和载体的方法和组合物
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
CN110836966A (zh) * 2018-08-15 2020-02-25 王镕 用于抗原特异性t细胞含量检测的检测纳米颗粒、检测方法及试剂盒等
US12384890B2 (en) 2018-10-18 2025-08-12 The Regents Of The University Of California Methods for fabricating modular hydrogels from macromolecules with orthogonal physico-chemical responsivity
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3962537A1 (en) 2019-04-28 2022-03-09 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
CN110221081B (zh) * 2019-06-26 2023-01-24 上海执诚生物科技有限公司 视黄醇结合蛋白胶乳试剂r2及其制备方法和试剂盒
BR112022000374A2 (pt) * 2019-07-11 2022-05-10 Newleaf Symbiotics Inc Composições microbianas
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
CA3152525A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
EP4048269A1 (en) 2019-10-21 2022-08-31 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
CN118384281A (zh) 2019-11-08 2024-07-26 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
CN119236187A (zh) 2020-02-21 2025-01-03 吉益医疗公司 聚合物包封的药物颗粒
AU2021225955A1 (en) 2020-02-26 2022-09-22 Selecta Biosciences, Inc. Methods and compositions using synthetic nanocarriers comprising immunosuppressant
IL297274A (en) 2020-04-14 2022-12-01 Selecta Biosciences Inc Methods and compositions for inducing autophagy
CN115697176A (zh) 2020-06-05 2023-02-03 库克医学技术有限责任公司 用于递送治疗剂的医疗窥镜
EP4164602A1 (en) * 2020-06-16 2023-04-19 Oxford University Innovation Limited Biodegradable multi-cavity microparticles and their use in treatment
WO2022084929A1 (en) * 2020-10-23 2022-04-28 Universita' Degli Studi Di Modena E Reggio Emilia Nanoparticles for transport across the blood-brain barrier
MX2023005224A (es) 2020-11-04 2023-07-18 Selecta Biosciences Inc Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas.
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
KR20230167405A (ko) 2021-04-09 2023-12-08 셀렉타 바이오사이언시즈, 인크. 면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US20240279687A1 (en) 2021-06-07 2024-08-22 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2023287654A1 (en) 2021-07-14 2023-01-19 Cook Medical Technologies, LLC Systems and methods for preventing clogging of a delivery system
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment
JP2024545594A (ja) 2021-11-14 2024-12-10 カーティザン セラピューティクス，インコーポレーテッド ウイルスベクターでの複数回投薬
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
CN120813689A (zh) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法
US12496429B2 (en) 2022-10-18 2025-12-16 Cook Medical Technologies Llc Systems and methods for delivering pressurized fluid to a target site alone or in conjunction with therapeutic agents
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
US12611313B2 (en) 2023-04-06 2026-04-28 33 Medical, Inc. Minimally invasive compliant devices for total lumbar disc replacement
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
KR20260021016A (ko) 2023-06-02 2026-02-12 33 메디칼, 인크. 추간판성 통증의 치료를 위한 조성물, 및 그의 제조 및 사용 방법
WO2025024693A1 (en) 2023-07-25 2025-01-30 Massachusetts Institute Of Technology Compositions and methods for treating fan1 associated trinucleotide repeat expansion disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504042A (ja) * 1993-07-23 1997-04-22 マサチューセッツ インスティテュート オブ テクノロジー 生分解性粒子

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2650306A1 (de) * 1976-11-02 1978-05-03 Merck Patent Gmbh Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4384996A (en) * 1981-01-09 1983-05-24 Sandoz Ltd. Novel cyclosporins
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
US5227467A (en) * 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
US5284826A (en) * 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5202332A (en) * 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5169851A (en) * 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP0752245B1 (en) * 1995-07-05 2002-05-22 European Community Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
US5709797A (en) * 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
IL140899A0 (en) * 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
US6551990B2 (en) 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
AU2002217760A1 (en) * 2000-10-12 2002-04-22 The University Of Tennessee Research Corporation Targeting drug/gene carriers to irradiated tissue
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US6544543B1 (en) * 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
CA2445125A1 (en) * 2001-03-21 2002-10-03 University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
WO2003048298A2 (en) * 2001-12-05 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
JP3690602B2 (ja) * 2002-06-19 2005-08-31 株式会社オーエムソーラー協会 空気式ソーラーシステム
US20050100877A1 (en) * 2003-09-02 2005-05-12 University Of North Carolina At Chapel Hill Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpolulations and in cryopreservation, culture and transplantation of cells
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504042A (ja) * 1993-07-23 1997-04-22 マサチューセッツ インスティテュート オブ テクノロジー 生分解性粒子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6011049102; Ｊ　Ｂｉｏｍｅｄ　Ｍａｔｅｒ　Ｒｅｓ ６６Ａ, 2003, ｐ．５５-６１ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016128404A (ja) * 2009-03-31 2016-07-14 ユニベルシテ ダンジュ 官能化された脂質カプセルを調製する為の方法
JP2013540162A (ja) * 2010-10-22 2013-10-31 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 抗原特異的な寛容を誘導する微粒子およびその使用
JP2016536312A (ja) * 2013-11-01 2016-11-24 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法のための調節粒子
JP2020073617A (ja) * 2013-11-01 2020-05-14 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法のための調節粒子
US10751291B2 (en) 2013-11-01 2020-08-25 Yale University Nanoparticulate compositions comprising interferon gamma and losartan for immunotherapy
WO2022050369A1 (ja) 2020-09-04 2022-03-10 国立大学法人大阪大学 抗菌薬を含有するリポソーム製剤

Also Published As

Publication number Publication date
US20060002971A1 (en) 2006-01-05
AU2009201301A1 (en) 2009-04-23
AU2005326322A1 (en) 2006-08-03
JP2015007139A (ja) 2015-01-15
US20080014144A1 (en) 2008-01-17
EP1768692A2 (en) 2007-04-04
EP1768692A4 (en) 2012-05-02
WO2006080951A3 (en) 2007-12-27
JP6031077B2 (ja) 2016-11-24
US7534449B2 (en) 2009-05-19
US20090269397A1 (en) 2009-10-29
US7550154B2 (en) 2009-06-23
EP1768692B8 (en) 2015-06-17
JP2016193947A (ja) 2016-11-17
WO2006080951A8 (en) 2008-08-14
CA2571899A1 (en) 2006-08-03
US7534448B2 (en) 2009-05-19
AU2005326322B2 (en) 2009-02-05
WO2006080951A2 (en) 2006-08-03
US20060002852A1 (en) 2006-01-05
US20090239789A1 (en) 2009-09-24
JP2018100295A (ja) 2018-06-28
AU2009201301B2 (en) 2012-10-18
JP6407218B2 (ja) 2018-10-17
EP1768692B1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
JP6407218B2 (ja) 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US11896686B2 (en) Hyperbranched polyglycerol-coated particles and methods of making and using thereof
AU2005237270B2 (en) Pegylated nanoparticles
JP5506196B2 (ja) 免疫治療のためのナノ粒子
Wafa et al. Single dose of a polyanhydride particle-based vaccine generates potent antigen-specific antitumor immune responses
Lin Development of targeting nanoparticles mimicking the adhesive properties of platelets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120910

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121003

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150805